Duopharma Biotech Bhd
KLSE:DPHARMA
Intrinsic Value
The intrinsic value of one DPHARMA stock under the Base Case scenario is 1.73 MYR. Compared to the current market price of 1.22 MYR, Duopharma Biotech Bhd is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Duopharma Biotech Bhd
Fundamental Analysis


Revenue & Expenses Breakdown
Duopharma Biotech Bhd
Balance Sheet Decomposition
Duopharma Biotech Bhd
Current Assets | 725.3m |
Cash & Short-Term Investments | 260.4m |
Receivables | 244.9m |
Other Current Assets | 220m |
Non-Current Assets | 627.6m |
Long-Term Investments | 25.3m |
PP&E | 557.9m |
Intangibles | 37m |
Other Non-Current Assets | 7.5m |
Free Cash Flow Analysis
Duopharma Biotech Bhd
MYR | |
Free Cash Flow | MYR |
Earnings Waterfall
Duopharma Biotech Bhd
Revenue
|
787.5m
MYR
|
Cost of Revenue
|
-506.1m
MYR
|
Gross Profit
|
281.4m
MYR
|
Operating Expenses
|
-191.6m
MYR
|
Operating Income
|
89.8m
MYR
|
Other Expenses
|
-33.8m
MYR
|
Net Income
|
56.1m
MYR
|
DPHARMA Profitability Score
Profitability Due Diligence
Duopharma Biotech Bhd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Duopharma Biotech Bhd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
DPHARMA Solvency Score
Solvency Due Diligence
Duopharma Biotech Bhd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Duopharma Biotech Bhd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DPHARMA Price Targets Summary
Duopharma Biotech Bhd
According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.53 MYR with a low forecast of 1.4 MYR and a high forecast of 1.7 MYR.
Dividends
Current shareholder yield for DPHARMA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one DPHARMA stock under the Base Case scenario is 1.73 MYR.
Compared to the current market price of 1.22 MYR, Duopharma Biotech Bhd is Undervalued by 29%.